PIRS Pieris Pharmaceuticals, Inc.

4.81
-0.04  -1%
Previous Close 4.85
Open 4.82
Price To book 11.58
Market Cap 207.16M
Shares 43,068,000
Volume 666,105
Short Ratio 0.31
Av. Daily Volume 1,056,750

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b data released at ERA-EDTA June 4, 2017.
PRS-080
Anemia of chronic disease

Latest News

  1. Pieris Pharmaceuticals Announces Expiration of HSR Waiting Period for Collaboration with AstraZeneca
  2. Pieris Pharmaceuticals Announces Presentation of Clinical Data for Anemia Drug Candidate, PRS-080, at the 54th ERA-EDTA Congress
  3. Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
  4. Pieris Pharmaceuticals to Present at The Jefferies 2017 Global Healthcare Conference on Friday, June 9th at 9:00 am EDT
  5. Pieris Pharmaceuticals Appoints James Geraghty to its Board of Directors
  6. Pieris Pharmaceuticals reports 1Q loss
  7. Pieris Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2017 and Provides Corporate Update
  8. Blog Coverage: Pieris Announces Collaboration with AstraZeneca
  9. Boston-based Pieris adds AstraZeneca as R&D partner in $45M deal
  10. Pieris Pharma stock soars 54% on news of $57.5 mln AstraZeneca deal
  11. Pieris Pharmaceuticals to Host Conference Call on Strategic Alliance With AstraZeneca
  12. AstraZeneca boosts early respiratory medicine with Pieris deal
  13. Pieris Pharmaceuticals and AstraZeneca Collaborate to Develop and Commercialize Anticalin-Based Inhaled Treatments for Respiratory Diseases
  14. Pieris Pharmaceuticals to Host First Quarter 2017 Investor Call and Corporate Update on May 11, 2017
  15. Pieris Pharmaceuticals Presents IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, in Poster Session at the 2017 Meeting of the American Association for Cancer Research (AACR)
  16. Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017
  17. Pieris Pharmaceuticals Reports Full-Year 2016 Financial Results and Corporate Update
  18. Pieris Pharmaceuticals to Host Full-Year 2016 Investor Call And Corporate Update on March 23, 2017
  19. Pieris Pharmaceuticals to Present at Oppenheimer's 27th Annual Healthcare Conference, Wednesday, March 22nd at 11:30 am EDT
  20. Pieris Pharmaceuticals to Present at the 29th Annual Roth Conference Monday, March 13th at 2:00 pm PST

SEC Filings

  1. 8-K - Current report 17890057
  2. 8-K - Current report 17861903
  3. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17849425
  4. DEF 14A - Other definitive proxy statements 17849389
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17845459
  6. 8-K - Current report 17832424
  7. 8-K - Current report 17807110
  8. 8-K - Current report 17736219
  9. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17723302
  10. 8-K - Current report 17707984